Table 1 Baseline characteristics of ESCC patients in the training and validation sets
|  | Training set (n = 276, %) | Validation set (n = 119, %) | P value |
|---|---|---|---|
Age (mean ± SD, years) | 59.0 ± 7.9 | 57.9 ± 7.7 | 0.177 |
Gender (male/female) | 188(68.1)/88(31.9) | 94(79.0)/25(21.0) | 0.028 |
Tumor length (mean ± SD, cm) | 4.2 ± 1.8 | 4 .3 ± 1.7 | 0.761 |
Tumor location (upper/middle/lower) | 17(6.2)/122(44.2)/137(49.6) | 10(8.4)/54(45.4)/55(46.2) | 0.658 |
Vessel invasion (no/yes) | 231(83.7)/45(16.3) | 99(83.2)/20(16.8) | 0.902 |
Perineural invasion (no/yes) | 221(80.1)/55(19.9) | 97(81.5)/22(18.5) | 0.740 |
Differentiation (well/moderate/poor) | 41(14.9)/184(66.7)/51(18.4) | 17(14.3)/78(65.5)/24(20.2) | 0.924 |
TNM stage (I/II/III) | 79(28.6)/94(34.1)/103(37.3) | 33(27.7)/46(38.7)/40(33.6) | 0.659 |
Adjuvant treatment (no/yes) | 198(71.7)/78(28.3) | 87(73.1)/32(26.9) | 0.780 |
CRP (mean ± SD, mg/L) | 7.2 ± 8.0 | 7.6 ± 7.9 | 0.633 |
ALB (mean ± SD, g/dL) | 4.1 ± 0.5 | 4.0 ± 0.5 | 0.454 |
PLT (mean ± SD, 10^9/L) | 224 ± 71 | 225 ± 75 | 0.935 |
TNC (mean ± SD, 10^9/L) | 4.42 ± 1.54 | 4.55 ± 1.62 | 0.471 |
TLC (mean ± SD, 10^9/L) | 1.58 ± 0.5 | 1.54 ± 0.4 | 0.395 |
TMC (mean ± SD, 10^9/L) | 0.52 ± 0.20 | 0.50 ± 0.13 | 0.548 |
PNI (mean ± SD) | 48.6 ± 5.5 | 48.0 ± 6.0 | 0.297 |
SII (mean ± SD) | 674.9 ± 355.5 | 720.4 ± 416.8 | 0.269 |
OPS (0/1/2/3) | 85(30.8)/124(44.9)/52(18.8)/15(5.5) | 38(31.9)/51(42.9)/19(16.0)/11(9.2) | 0.507 |
GPS (0/1/2) | 182(65.9)/69(25.0)/25(9.1) | 78(65.5)/29(24.4)/12(10.1) | 0.947 |
SIS (0/1/2) | 140(50.7)/118(42.8)/18(6.5) | 63(52.9)/51(42.9)/5(4.2) | 0.654 |